The independent source for health policy research, polling, and news.
621-640 of 1,314 results
The National Institutes of Health has suggested minorities should be overrepresented in COVID-19 vaccine trials â perhaps at rates that are double their percentage of the U.S. population. But efforts to recruit patients from racial minority groups are just beginning, while some trials have already advanced to phase 3.
The AstraZeneca trial is on hold in the U.S. as scientists try to unravel whether a rare neurological condition is linked to the vaccine. But regulators are frustrated by a lack of information from the drugmaker.
The nationâs top infectious disease official is confident that an independent panel will base vaccine approval on science, not politics.
California could become the first state to develop its own line of generic drugs under a bill approved Monday by the legislature. The measure heads to Gov. Gavin Newsom for consideration.
Donald Trump accepted his party's nomination to seek reelection for a second term as president in front of a partisan audience that appeared to largely lack masks and opt against social distancing.
During his Monday speech at the Republican National Convention, President Donald Trump pointed to his two of his recent executive orders as likely to lead to big reductions in prescription drug costs.
Harbor-UCLA Medical Center serves patients who are especially vulnerable to the coronavirus: They are essential workers, have chronic diseases and are members of underrepresented racial and ethnic groups. When the safety-net hospital kicks off enrollment for its COVID-19 vaccine trial Wednesday, it will look to those patients to participate.
The impact of the novel coronavirus, and the current administration's response to it, were central themes in Joe Biden's presidential nomination acceptance speech.
In a highly produced, made-for-TV political convention, Democrats papered over their differences on a variety of issues, including health care, to show a unified front to defeat President Donald Trump in November. Meanwhile, COVID-19 continues to complicate efforts to get students back to school, and a federal judge blocks the Trump administrationâs efforts to eliminate anti-discrimination protections for transgender people. Margot Sanger-Katz of The New York Times, Paige Winfield Cunningham of The Washington Post and Shefali Luthra of The 19th join KHNâs Julie Rovner to discuss this and more. Plus, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.
The Democratic presidential ticket is complete, with Joe Bidenâs selection of California Sen. Kamala Harris as his running mate. Health has not been a major issue for Harris, whose career priority has been the criminal justice system. But expect Republicans to pounce on her on-again, off-again support for âMedicare for All.â Meanwhile, with Congress still in a stalemate over another round of COVID-19 relief, President Donald Trump is trying to use his executive power to do what lawmakers have not â with mixed success. Kimberly Leonard of Business Insider, Joanne Kenen of Politico and Mary Agnes Carey of KHN join KHNâs Julie Rovner to discuss this and more. Plus, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.
Experts say folks 60 and up must continue to limit exposure in the years to come â even after there is a vaccine for COVID-19.
Teams are starting to test vaccines using messenger RNA or chimpanzee cold viruses to inoculate humans. Will their benefits last?
This statement is taken from a video in which a group of doctors air unproven conspiracy theories about the coronavirus. Dr. Immanuel's claims were among the most inaccurate. And, before it was removed from social media platforms, thee video was viewed millions of times. President Donald Trump retweeted it.
President Donald Trumpâs sobering view of COVID-19 didnât last long â this week, he was back to pushing hydroxychloroquine, a drug that has been shown not to work in treating the virus. Meanwhile, Republicans on Capitol Hill are still scrambling to agree among themselves and with the White House on the next coronavirus relief bill, as both a moratorium on evictions and extra unemployment payments expire. And the debate over drug prices, which was going to be one of the biggest health issues of this election year, makes a brief appearance. Alice Miranda Ollstein of Politico, Mary Ellen McIntire of CQ Roll Call and Anna Edney of Bloomberg News join KHNâs Julie Rovner to discuss this and more. Also, Rovner interviews KHNâs Markian Hawryluk, who wrote the latest KHN-NPR âBill of the Monthâ story about a surprise bill from a surprise surgical assistant.
The FDA must approve any coronavirus vaccine before itâs widely distributed, but political pressure could cloud the decision.
Newsletter editor Lauren Olsen wades through hundreds of health care policy stories each week, so you donât have to.
Under ordinary circumstances, these phases of vaccine development can take years to complete. But now, during the age of coronavirus, the timeline is being shortened. Here's an inventory of where things stand.
A rule finalized this spring by the Trump administration permits employers and insurers not to apply drug company copayment assistance toward enrolleesâ deductibles and out-of-pocket maximums for any drug.
The Trump administration rolled back protections for transgender patients just days before the Supreme Court cemented LGBTQ rights under the Civil Rights Act. So, what now? Meanwhile, coronavirus politics reaches beyond health care settings. Anna Edney of Bloomberg News, Tami Luhby of CNN and Shefali Luthra of KHN join KHNâs Julie Rovner to discuss this and more. Also, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.
KHN executive editor Damon Darlin wades through mounds of health care policy stories â so you donât have to.
© 2026 51ÊÓÆ”